DexCom (DXCM) shares surged 6.60% in Thursday's trading session following the company's release of its first-quarter 2025 financial results, which exceeded analyst expectations on the top line. The medical device maker, known for its continuous glucose monitoring systems, also announced a new $750 million share repurchase program, further bolstering investor confidence.

For the first quarter, DexCom reported revenue of $1.036 billion, representing a 12% year-over-year increase and surpassing Wall Street estimates of $1.017 billion. The company's adjusted earnings per share came in at $0.32, in line with the previous year but slightly below the consensus estimate of $0.33. Despite the minor earnings miss, investors focused on the strong revenue growth and positive outlook.

Kevin Sayer, DexCom's chairman, president, and CEO, commented on the results, stating, "To start the year, DexCom delivered a quarter of strong revenue results and unlocked significant new type 2 coverage." The company maintained its full-year 2025 revenue guidance of $4.60 billion, representing a 14% growth rate, which aligns closely with analyst expectations of $4.61 billion. This reaffirmation of guidance, coupled with the revenue beat, likely contributed to the stock's significant uptick.

Adding to the positive sentiment, DexCom's board of directors authorized a new $750 million share repurchase program. This move signals management's confidence in the company's financial position and future prospects, potentially providing additional support for the stock price. The repurchase program is set to run through June 30, 2026, giving the company flexibility in its capital allocation strategy.